Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses
Buruli ulcer (BU), caused by Mycobacterium ulcerans, is currently treated with a daily combination of rifampin and either injectable streptomycin or oral clarithromycin. An intermittent oral regimen would facilitate treatment supervision. We first evaluated the bactericidal activity of newer antimic...
Main Authors: | Chauffour, Aurélie, Robert, Jérôme, Veziris, Nicolas, Aubry, Alexandra, Pethe, Kevin, Jarlier, Vincent |
---|---|
Other Authors: | Lee Kong Chian School of Medicine (LKCMedicine) |
Format: | Journal Article |
Language: | English |
Published: |
2021
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/148764 |
Similar Items
-
Derivatives : an Asian perspective.
by: Lim, Candy Tian Ni., et al.
Published: (2010) -
A study of five derivatives markets in the Asia-Pacific Basin
by: Lai Ping, et al.
Published: (2014) -
Re-understanding the mechanisms of action of the anti-mycobacterial drug bedaquiline
by: Sarathy, Jickky Palmae, et al.
Published: (2020) -
Hierarchical NiCo-LDH core/shell homostructural electrodes with MOF-derived shell for electrochemical energy storage
by: Zheng, Kun, et al.
Published: (2022) -
Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy
by: Goh, Wei Jiang, et al.
Published: (2017)